Novartis halts UK trial of anticholesterol drug Leqvio

Published On 2023-03-23T18:00:08+05:30 | Updated On 24 March 2023 9:52 AM GMT

Overview

Novartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally planned as part of its partnership with NHS England to investigate the potential of the anti-cholesterol drug Leqvio.

"After careful evaluation, we have decided not to move forward with ORION-17," a spokesperson said in an emailed statement. "We continue to have very high ambitions for Leqvio and are encouraged by the foundation we have built and the traction we have seen so far, both in the UK and around the world."

For more details, check out the link given below:

Novartis Not To Move Ahead With UK Trial Of Anti-Cholesterol Drug Leqvio

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751